Related Experiment Video
Updated: Apr 17, 2026
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[Diagnosis and therapy of chronic hepatitis B: Czech national guidelines]
Petr Husa1, Jan Šperl, Petr Urbánek
1Clinic of Infectious Diseases, Faculty of Medicine, Masaryk University and University Hospital Brno, Czech Republic,
Insights
New Czech guidelines for chronic hepatitis B (HBV) treatment are updated. Treatment aims to suppress HBV replication, preventing liver damage and improving patient quality of life.
Area of Science:
- Hepatology
- Virology
- Internal Medicine
Background:
- Chronic hepatitis B (HBV) affects 350-400 million globally, with low prevalence (0.56%) in the Czech Republic.
- HBV infection can cause severe liver damage, including cirrhosis and hepatocellular carcinoma (HCC).
- Treatment goals focus on prolonging life and preventing disease progression through sustained viral suppression.
Purpose of the Study:
- To present updated recommendations for managing chronic hepatitis B (HBV) in the Czech Republic.
- To outline current treatment strategies for HBV infection based on new knowledge.
- To emphasize the importance of sustained viral suppression in managing HBV.
Main Methods:
- Review of recent scientific knowledge and clinical studies on chronic hepatitis B.
- Analysis of treatment strategies including finite-duration and long-term therapies.
- Evaluation of antiviral agents such as pegylated interferon (PEG-IFN), entecavir (ETV), and tenofovir (TDV).
Main Results:
- Two primary treatment strategies are available: finite-duration and long-term therapy.
- Finite-duration treatment with PEG-IFN, ETV, or TDV is recommended for specific patient groups, often requiring 12 months post-seroconversion.
- Long-term ETV or TDV therapy is indicated for non-responders, HBeAg-negative patients, and those with cirrhosis.
Conclusions:
- Sustained suppression of HBV replication is key to preventing liver disease progression.
- Treatment choice depends on HBeAg status, seroconversion, and presence of cirrhosis.
- ETV and TDV offer potent options with favorable resistance profiles for chronic hepatitis B management.
Abstract:
The new recommendations reflect the increase in knowledge that has been reported since the release of previous Czech guidelines in April 2009. According to qualified estimates, there are 350-400 million people with chronic hepatitis B (HBV) infection worldwide. The Czech Republic is among the countries with a low prevalence of HBV infection. According to the latest seroprevalent study, 0.56 % of the Czech citizens were chronically infected with HBV in 2001. HBV infection can lead to serious life-threatening liver damage - fulminant hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC). The goals of treatment are to prolong the length of life and improve its quality by preventing the progression of chronic hepatitis to cirrhosis, cirrhosis decompensation and development of HCC. The goals can be achieved if HBV replication is suppressed in a sustained manner. Then, the accompanying reduction in histological activity lowers the risk of cirrhosis and HCC, particularly in non-cirrhotic patients. Currently, two different strategies for treating chronic hepatitis B are available. Treatment of finite duration is with pegylated interferon (PEG-IFN), entecavir (ETV), or tenofovir (TDV). A 48-week course of PEG-IFN is mainly recommended for HBeAg-positive patients with the best chance of anti-HBe seroconversion. Finite-duration of ETV or TDV treatment is available for HBeAg-positive patients who seroconvert to anti-HBe on treatment. However, treatment duration is unpredictable prior to the therapy as it depends on the timing of anti-HBe seroconversion and the treatment continuation following anti-HBe seroconversion (therapy should be prolonged for additional 12 months after anti-HBe seroconversion). Long-term ETV or TDV therapy is necessary for HBeAg-positive patients who do not develop anti-HBe seroconversion and for HBeAg-negative patients. This strategy is also recommended for patients with cirrhosis irrespective of the initial HBeAg status or anti-HBe seroconversion on treatment. The advantage of ETV and TDV is based on their high potency and optimal resistance profile.
Related Concept Videos
01:25Hepatitis
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:28Chronic Kidney Disease III: Interprofessional Care
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...